Abcellera Biologics Inc. · NASDAQ:ABCL
Abcellera Biologics — Investor Presentation (January 2026)
32 slides from Abcellera Biologics's investor presentation, Jan 14, 2026
Slide 1: AbCellera Corporate Overview
CO PY RI GH T © A BC EL LE RA January 14, 2025 AbCellera Corporate Overview
Slide 2: Disclaimer
These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are d
Slide 3: We are a clinical-stage biotech company focused on developing novel antibody medicines
3 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew We are a clinical-stage biotech company focused on developing novel antibody medicines. Founded: 2012 Employees: ~600 Locations: Vancouver & Montreal, Canada Sydney, Australia IPO: December 2020 Liquidity: $680M* Partnerships* 100+ Programs 4
Slide 4: Our platform was built through 10+ years of drug discovery partnerships
4 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew Our platform was built through 10+ years of drug discovery partnerships. Since 2014, we have partnered with some of the industry’s most innovative pharma and biotech companies. Partnerships were a driver for R&D, and provided near-term revenu
Slide 5: Use our competitive advantage in antibody drug creation to build a pipeline
5 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew Use our competitive advantage in antibody drug creation to build a pipeline of differentiated assets. STRATEGY Discovery for GPCR and ion channel targets Novel modalities, including multi-specifics and ADCs Indication agnostic
Slide 6: Two programs in the clinic, two in IND-enabling, and 20+ in discovery
6 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew Two programs in the clinic, two programs in IND-enabling activities, and 20+ programs in discovery. INTERNAL PIPELINE & PROGRAMS 20+ discovery programs in the pipeline MOLECULE TARGET THERAPEUTIC AREA STAGE Discovery IND-Enabling Phase 1 Phas
Slide 7: 2025 Priorities
7 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew 2025 PRIORITIES As of September 30, 2025 Clinical trials on track, completed platform investments, and started activities at clinical manufacturing site. ABCL635 Phase 1/2 clinical trial initiated (June 2025) ABCL575 Phase 1 clinical trial in
Slide 8: Advance pipeline to key data readouts for ABCL635 and ABCL575
8 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew Advance pipeline to key data readouts for ABCL635 and ABCL575, and set up for additional three INDs in 2027. Nominate at least 1 additional development candidate for IND-enabling studies 2026 PRIORITIES ABCL635 Phase 1 clinical trials topline
Slide 9: Two readouts in 2026 & potential for multiple catalysts in 2027
9 CO PY RI GH T © A BC EL LE RA Q1 Q2 Q3 Q4 Co rp or at e Ov er vi ew Two readouts in 2026 & potential for multiple catalysts in 2027. 2026 ABCL635 Menopausal VMS ABCL635 VMS in Oncology ABCL575 Inflammation & Autoimmunity ABCL386 Oncology ABCL688 Autoimmunity New Development Candidate Development c
Slide 10: Internal Programs
10 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew Internal Programs
Slide 11: We are unlocking high-value drug targets
11 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew *As of December 31, 2024 We are unlocking high-value drug targets. OUR PLATFORMS ● Clinically validated, membrane-protein targets with large commercial potential that have proven largely intractable using traditional methods for antibody dis
Slide 12: Internal Programs ABCL635
12 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew Internal Programs ABCL635
Slide 13: Internal Pipeline & Programs: ABCL635
13 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew INTERNAL PIPELINE & PROGRAMS Neurokinin 3 receptor (NK3R) Target G protein-coupled receptor (GPCR) Target Type Moderate-to-severe vasomotor symptoms (VMS) associated with menopause Indication Endocrinology / women’s health Therapeutic Area P
Slide 14: ABCL635 science, differentiation, commercial opportunity, development path
14 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew ● Potential for: ○ First-in-class antibody therapy ○ Enhanced efficacy ○ Differentiated safety profile ○ Monthly (Q4W) subcutaneous dosing schedule, preferred by women with VMS Science DifferentiationCommercial Opportunity Development Path ●
Slide 15: VMS are highly prevalent and significantly impact health and well-being
15 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew VMS are highly prevalent, significantly impact health and well-being, and are the most common reason for seeking treatment for menopause. 1. Avis NE, et al. JAMA Intern Med. 2015 Apr;175(4):531-9. doi: 10.1001/jamainternmed.2014.8063.. 2. Th
Slide 16: Large unmet need for many women suffering from VMS
16 CO PY RI GH T © A BC EL LE RA In a global study, 57% of women were eligible for MHT, but against using it.1 Co rp or at e Ov er vi ew 1. Stute P, et al. Maturitas. 2022 Oct;164:38-45. doi: 10.1016/j.maturitas.2022.06.008. 2. “The 2023 Nonhormone Therapy Position Statement of The North American Me
Slide 17: NK3R antagonists are effective, non-hormonal options for VMS
17 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew NK3R antagonists are effective, non-hormonal options for VMS. ABCL635 Science Pre-Menopause
Slide 18: NK3R antagonists are effective, non-hormonal options for VMS
18 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew NK3R antagonists are effective, non-hormonal options for VMS. ABCL635 Menopause Science
Slide 19: NK3R antagonists are effective, non-hormonal options for VMS
19 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew NK3R antagonists are effective, non-hormonal options for VMS. ABCL635 Treatment Science Proposed mechanism of action for ABCL635 based on AbCellera nonclinical data and published literature.
Slide 20: Recently approved NK3R therapies are building the market
20 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew Recently approved NK3R therapies are building the market. ABCL635 Small molecule NK3R antagonist Approved by US FDA on May 12, 2023 Stage Daily oral treatment Dosing ● Effective in reducing severity and frequency of VMS. ● Boxed warning for
Slide 21: ABCL635 is designed to offer an improved treatment option
21 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew ABCL635 is designed to offer an improved treatment option for women with moderate-to-severe VMS due to menopause. 1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Di
Slide 22: Internal Programs ABCL575
22 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew Internal Programs ABCL575
Slide 23: ABCL575 is a potential best-in-class antibody for atopic dermatitis
23 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew ABCL575 is a potential best-in-class antibody for the treatment atopic dermatitis. INTERNAL PIPELINE & PROGRAMS OX40 Ligand (OX40L) Target Atopic Dermatitis (AD) Indication Immunology & Inflammation Therapeutic Area Phase 1 Status
Slide 24: ABCL575 science, differentiation, commercial opportunity, development path
24 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew INTERNAL PIPELINE & PROGRAMS ● Competitive space with two late stage programs targeting OX40L (amlitelimab) and OX40 (rocatilimab) ● ABCL575 expected to support Q24W or longer dosing schedule Science DifferentiationCommercial Opportunity Dev
Slide 25: ABCL575 targets multiple immune pathways
25 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew ABCL575 targets multiple immune pathways. ABCL575 Science Atopic Dermatitis
Slide 26: ABCL575 targets multiple immune pathways
26 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew ABCL575 targets multiple immune pathways. ABCL575 Science Treatment Proposed mechanism of action for ABCL575 based on AbCellera nonclinical data and published literature.
Slide 27: Royalty Portfolio & Partnered Programs
27 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew Royalty Portfolio & Partnered Programs
Slide 28: We built industry-leading capabilities through partnerships
28 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew We built industry- leading capabilities through partnerships with the top-tier of biotech and pharma partners. ● Validated on 100+ therapeutic programs over the past 10+ years ● Leading capabilities on difficult targets and bispecifics ● A p
Slide 29: Partnerships have built a large portfolio of royalties
29 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew Partnerships have built a large portfolio of royalties in future antibody medicines. The value of this portfolio will mature over time as our partners advance these programs into the clinic and beyond. * For programs started by March 31, 202
Slide 30: Partner-initiated programs continue to progress towards the clinic
30 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew Partner-initiated programs continue to progress towards the clinic. PARTNER-INITIATED PROGRAMS WITH DOWNSTREAM PARTICIPATION*Cumulative # of *Excludes AbCellera-initiated and Trianni-license program. As of December 31, 2024. Historical resul
Slide 31: A cumulative total of molecules have reached the clinic
31 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew A cumulative total of 16 molecules have reached the clinic. MOLECULE MOST ADVANCED STAGE THERAPEUTIC AREA(S) PARTNER PROGRAM TYPE bamlanivimab (LY-CoV555) Marketed, Emergency Use Authorization (EUA)* • infectious disease: COVID-19 AbCellera-
Slide 32: Thank You
32 CO PY RI GH T © A BC EL LE RA Co rp or at e Ov er vi ew THANK YOU
AbCellera Biologics — Investor Presentation (January 2026) on 6ix